Author

Kevin Mohammed

Icahn School of Medicine at Mount SinaiORCID 0000-0002-9955-9407Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

Ernesto GuccioneiD· 2 shared Alexander M. TsankoviD· 1 shared Ana Orive-RamosiD· 1 shared Beau BaarsiD· 1 shared Bijaya GaireiD· 1 shared Bruno GiottiiD· 1 shared Christos AdamopoulosiD· 1 shared Dan HassoniD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Ernesto GuccioneORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyCancer DiscoveryPeer-reviewedSep 29, 2026

Spatial modulation of RAF by RAF/MEK glue enables full-dose combination with pan-RAF inhibitor and potent RAS-mutant tumor-selective MAPK and growth inhibition

Ana Orive-Ramos, Bijaya Gaire, Christos Adamopoulos…·Poulikos I. Poulikakos

The paper shows RAF/MEK glues enable full-dose combination with pan-RAF inhibitors, enhancing tumor-selective MAPK inhibition and tumor regression in RAS-mutant models.

DOI 10.1158/2159-8290.cd-25-1596

humanproteomics

𝕏 PostBluesky

Cancer BiologyNature GeneticsPeer-reviewedFeb 1, 2025

A Mutation-driven oncofetal regression fuels phenotypic plasticity in colorectal cancer

Slim Mzoughi, Megan Catherine Schwarz, Xuedi Wang…·Ernesto Guccione

This study identifies an oncofetal cell state that contributes to resistance in colorectal cancer and shows that targeting both this state and LGR5+ CSCs is needed for effective treatment.

97 citationstop 1%

humanbulk RNA-seq

𝕏 PostBluesky